Key result
SARS-CoV-2 vaccines have been associated with rare neurological adverse events such as cerebral venous sinus thrombosis, though clear evidence of causal associations is currently lacking.
Why the study?
Neurological adverse events following SARS-CoV-2 immunisation prompted vaccine program pauses despite a lack of clear evidence of causal associations.
This review highlights the need for careful causality assessment of rare neurological complications, such as cerebral venous sinus thrombosis, following SARS-CoV-2 vaccination.
Neurological AEFI after COVID-19 vaccination warrant ongoing surveillance; leaves open causality and risk-benefit implications.
The scientific community rapidly responded to the COVID-19 pandemic by developing novel SARS-CoV-2 vaccines (table 1). As of early June 2021, an estimated 2 billion doses have been administered worldwide.1 Neurological adverse events following immunisation (AEFI), such as cerebral venous sinus thrombosis and demyelinating episodes, have been reported. In some countries, these have led to the temporary halting of both vaccine trials and roll-out programmes. In the absence of clear evidence of causal associations between the vaccine and adverse events, or the rarity of the AEFIs themselves, programmes have thus far been restarted, although sometimes with modifications to recommendations.
No takes yet. Share an insight, caveat, or question.
Butler et al. (2021) conducted a review in Neurological adverse events following immunisation. SARS-CoV-2 vaccines was evaluated on Neurological adverse events following immunisation (AEFI). SARS-CoV-2 vaccines have been associated with rare neurological adverse events such as cerebral venous sinus thrombosis, though clear evidence of causal associations is currently lacking.